{"id":134118,"date":"2026-08-09T10:19:20","date_gmt":"2026-08-09T10:19:20","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/134118\/"},"modified":"2026-08-09T10:19:20","modified_gmt":"2026-08-09T10:19:20","slug":"doximity-docs-stock-fair-value-rises-after-split-analyst-views-on-ai-growth","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/134118\/","title":{"rendered":"Doximity (DOCS) Stock Fair Value Rises After Split Analyst Views On AI Growth"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St. <\/p>\n

Doximity’s updated fair value estimate has moved from US$24.37 to US$28.00, which represents roughly a 15% uplift in the latest model. This shift lines up with the split analyst narrative, where some firms point to improving execution and AI traction, while others focus on execution risk, competition in healthcare AI, and the path for longer term growth. As you read on, you will see how to track these changing views and what to watch as the story around Doximity continues to evolve. <\/p>\n

Stay updated as the Fair Value for Doximity<\/a> shifts by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Doximity. <\/p>\n

What Wall Street Has Been Saying \ud83d\udc02 Bullish Takeaways <\/p>\n

Needham and Raymond James recently raised their Doximity price targets to US$41 and US$38, citing what they describe as a solid Q1 report, stabilizing results, and early positive commentary around AI Search and broader AI commercialization. <\/p>\n

Several firms including Canaccord, Raymond James, and BMO highlight Doximity’s AI Search traction and expanding Clinical Suite adoption as potential supports for future monetization and what they view as a more constructive long term growth setup. <\/p>\n

Needham and Morgan Stanley acknowledge recent execution issues but still see room for value creation as Doximity invests into AI and seeks a larger share of pharma marketing budgets. <\/p>\n

\ud83d\udc3b Bearish Takeaways <\/p>\n

BofA, Wells Fargo, Baird, BTIG, Jefferies, Barclays, and others have issued downgrades or lower targets, pointing to limited visibility on revenue and margins, execution risk around the AI pivot, and tougher competition from firms like Veeva and larger AI providers. <\/p>\n

Truist, Goldman Sachs, Mizuho, and KeyBanc emphasize slower growth expectations, heavier AI related spending that pressures margins, and softer industry conditions in digital pharma marketing, which they see as constraints on Doximity’s valuation until execution and growth trends become clearer. <\/p>\n

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!<\/a> <\/p>\n

\"NYSE:DOCS<\/a> NYSE:DOCS 1-Year Stock Price Chart <\/p>\n

We’ve flagged 2 risks for Doximity. See which could impact your investment.<\/a> <\/p>\n

How This Changes the Fair Value For Doximity <\/p>\n

Fair value moves from US$24.37 to US$28.00, which is about a 15% uplift in the updated model for Doximity. <\/p>\n

Revenue growth adjusts from 5.93% to 6.26% in the latest assumptions. <\/p>\n

Net profit margin moves from 27.68% to 27.95% in the refreshed estimates. <\/p>\n

Future P\/E is essentially stable, shifting slightly from 24.61x to 24.58x. <\/p>\n

The discount rate edges higher from 8.02% to 8.06% in the valuation work. <\/p>\n

Story Continues <\/p>\n

Never Miss an Update: Follow The Narrative <\/p>\n

Narratives connect Doximity’s business story to a set of financial expectations and a fair value framework. They refresh as new data, guidance, and research come through, so you can see how the story is changing over time. <\/p>\n

Head over to the Simply Wall St Community and follow the Narrative on Doximity<\/a> to stay up to date on: <\/p>\n

How AI workflow tools like Scribe, Doximity GPT, and Pathway AI are intended to deepen clinician engagement and support higher revenue per user over time. <\/p>\n

The role of pharma, SMB, and health system clients as they shift budgets toward digital marketing and Doximity’s broader clinician productivity and recruitment tools. <\/p>\n

Key risks such as heavy reliance on pharma marketing spend, policy and regulatory uncertainty, slowing user growth as clinician penetration matures, and higher AI related operating costs. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include DOCS<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":134119,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,25,66624,3305,66625,28414],"class_list":["post-134118","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ai","tag-ai","tag-artificial-intelligence","tag-doximity","tag-fair-value","tag-pharma-marketing","tag-raymond-james"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/134118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=134118"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/134118\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/134119"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=134118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=134118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=134118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}